Page 2 - Rna Interference News Today

Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report, 2023-2030" report has been...

Alnylam pioneered RNA interference drugs for rare disease. The biotech aims to bring RNAI to prevalent disorders and its alliance with Roche on the drug zilebesiran for hypertension better positions the company to achieve this goal.

Dublin, May 30, 2023 (GLOBE NEWSWIRE) -- The "Genomics Market Size, Share & Trends Analysis Report By Technology & Application (Functional...

ReNAgade Therapeutics has announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.

Dublin, April 27, 2023 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis...

Dublin, March 31, 2023 (GLOBE NEWSWIRE) -- The "RNA Analysis/Transcriptomics Global Market Report 2023" report has been added to ...

Dublin, March 16, 2023 (GLOBE NEWSWIRE) -- The "Global RNAi Therapeutics Market (by Molecule Type, Application, End-User & Region): Insights &...

During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2023 focused on continued commercial execution of four RNAi therapeutic products, and advancement of early-, mid-, and late-stage investigational programs.

Researchers illustrated a novel strategy likely employed by viruses to promote infection.

Recognition Marks Alnylam’s Eighth Year in a Row on this Prestigious List, and the Second Consecutive Year Ranking #1 -